Glucagon-like peptide 1 receptor agonists and the clinical outcomes of inflammatory bowel disease: a systematic review and meta-analysis.
Bayoumy. Ahmed B AB; Clarke. Lindsay M LM; Deepak. Parakkal P; Desai. Aakash A; Sehgal. Priya P; Gorelik. Uri U; Bar-Yoseph. Haggai H; Villumsen. Marie M; Mulder. Chris J J CJJ; Stenvers. Dirk J DJ; Tushuizen. Maarten E ME; de Boer. Nanne K H NKH
Key Findings
- Tirzepatide led to an average loss of ~11.8 kg after 3 months in obese IBD patients
- GLP‑1 receptor agonists cut the risk of IBD‑related surgery (logHR 0.61, OR 0.46)
- The protective effect on surgery and hospitalizations was strongest in patients with BMI ≥ 30
Practical Outcomes
- For biohackers with IBD and obesity, tirzepatide could be a powerful tool to shed weight and possibly lower the chance of needing surgery or hospital care. Start at the lowest approved dose, titrate slowly, and keep a close eye on gut symptoms and overall disease activity. Always coordinate with a gastroenterologist before adding it to your regimen.
Summary
A review of 11 studies shows that people with inflammatory bowel disease (IBD) who are also overweight can lose a lot of weight with drugs like tirzepatide (about 12 kg in three months) and may need fewer surgeries or hospital stays. The data are promising but still need solid clinical trials to confirm the benefits.
Abstract
Prior studies showed worse outcomes in obese inflammatory bowel disease (IBD) patients, especially those related to hospitalizations, surgery, and steroid-free remission. Glucagon-like peptide-1 receptor agonists (GLP1-RAs) have demonstrated significant metabolic benefits for patients with type 2 diabetes mellitus (T2DM) and obesity. Hence, GLP1-RAs may improve clinical outcomes in patients with IBD, especially those with obesity. The objective was to systematically evaluate the impact of GLP1-RAs on clinical outcomes in patients with IBD. A comprehensive literature search was performed using the databases PubMed, Embase, Web of Science, and Cochrane Library from inception to March 15, 2025. Studies reporting outcomes related to GLP1-RAs in patients with IBD were included. Primary outcomes included weight loss and various IBD-related co-endpoints such as hospitalizations, surgery, corticosteroid use, and advanced therapy initiation. In total, 11 studies with 16 242 patients with IBD treated with GLP1-RAs were included. Weight loss was achieved using semaglutide (-9.6 kg, 95% confidence interval [CI]: -12.0; -7.2), liraglutide (-9.4 kg, 95% CI: -13.0; -5.8), and tirzepatide (-11.8 kg, 95% CI: -18.3; -5.4) after 3 months of follow-up. In meta-analyses, GLP1-RAs were associated with lower risk of surgery for effect sizes (logHR: 0.61 [95% CI: 0.44-0.84], I 2 = 0%) and event frequencies (odds ratio [OR]: 0.46 [95% CI: 0.32-0.67], I 2 = 42%). Sensitivity analysis for body mass index (BMI) showed a lower risk of hospitalizations and surgery in patients with obesity (BMI ≥ 30). Patients with IBD and obesity using GLP1-RAs were able to achieve significant weight loss and had lower risks of surgery and hospitalizations. Our findings require confirmation in prospective trials of GLP1-RAs in IBD.
Study Information
pubmed
2025
2025-11-08T00:00:00.000Z
10.1093/ecco-jcc/jjaf181